Quantcast 7/13/13 - Genentech Secures FDA Priority Review For Perjeta Regimen Prior To Surgery - Congoo
 
 
BIOTECH Log In
7/13/13 - Genentech Secures FDA Priority Review for Perjeta Regimen Prior to Surgery
Have an interest in this Story?
Sign Up for Real-Time email updates
Pharmacy Choice  | July 13, 2013

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stag...
Read Full Article   
 
Leave a Comment: You must be logged in to leave a comment     Log in | Register
 

Featured Members
Sylvia M. Romagosa, MBA Sylvia M. Romagosa, MBA
Licensed Real Estate Broker
Real Estate Industry
Sergio Waldeck, MBA Sergio Waldeck, MBA
Director of Financial Planning and Analysis
Banking

  
  View more profiles

 
Access dozens of premium and subscriptions sites Free! Download now.

Advertise   |   Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms   |   Privacy   |   Need Help?   |   Site Map
Copyright ©2014 Congoo.com. All Rights Reserved.